MultiCell Technologies Inc (MCET)

[grandeur]

MCET(MultiCell Technologies, Inc.)**INTERESTING FINDS**-PLEASE STICKY THIS!
FINDS:
MCET:
1) addresses "unmet" medical needs for the treatment of neurological disorders, hepatic disease and cancer which means the company is creating different treatments that are not currently pre-existing.

2) Undervalued stock with partners...BRISTOL MYERS, PFIZER, MBI ,CORNING + more!
The preliminary tests have tested successful and MCET is on the right track which means room for great expansion!

3) La Jolla recently purchased shares of this stock, which means big things may be cooking! Why would someone purchase vast amounts of stock?....

4) In order for the therapies to be FDA approved, successful testing has to be implemented and a HUGE leap for MCET is the initiation of MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial. No current treatment exists for PMSF and with positive results in phase 1, MCET has now moved to phase 2 which shows they are definitely on the right track to great success!

5) Furthermore, many many pharmaceutical companies have taken off to cents and dollars we have sat and analyzed MCET and have formed our own opinion that MCET appears highly undervalued for its stage in the pharmaceutical industry. The pharmaceutical industry is a billion dollar industry and because MCET is currently in active phase 2 for the drug for PMSF (not currently available anywhere) MCET has a leverage above other stocks and other pharmaceutical companies in this way and others.

CRITICAL READ: OVERVIEW (BELOW)

The brain and spinal cord (CNS) is protected by Myelin sheath. In individuals with MS the Myelin sheath is destroyed by the body's own immune system and symptoms become apparent according to the severity of it. Once this destruction occurs, scar tissue forms on the damaged area and regular tissue does not regrow. This means that signals sent to and from the brain and spinal cord may be disrupted causing issues in coordination and such. In addition to this, Multiple Sclerosis is a leading Musculoskeletal disease that is effecting more and more people as time passes. This is why companies such as MCET, which are creating medications for diseases like MS, can become profitable in the future. The pharmaceutical industry is worth billions and there is a great need for research and medications for diseases that are becoming increasingly prevalent. We firmly believe MCET (MultiCell Technologies, Inc.) is headed in the right direction.

MCET focuses in on the fatigue related to MS: Primary Multiple Sclerosis-Related Fatigue (PMSF)
with effects a majority of individuals with Multiple Sclerosis and often leads to decreased ability to function and ultimately even a further reduction of health. How exactly does this happen? Well, people with MS have damaged myelin sheath (the protective covering of nerves in the CNS (Brain and Spinal Cord). The nerve signals cannot adequately reach their destination and may continue firing which can lead to fatigue. Currently there is no drug available for this fatigue and one of the things MCET is doing is working with researchers to create a drug for this.

E.g., MultiCell Technologies is working to Modulate “the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF) affecting over 70% of all persons with multiple sclerosis”

In addition to working to create treatments for PMSF, MCET is also doing a number of things including the following for the treatment of Cancer:

Control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, to treat cancer.
Enhance antigen presentation to the immune system by targeting antigen epitopes for optimal processing via the Fcg receptors through the novel generation of recombinant immunoglobulins for the treatment of cancer.
Enable generation and manipulation of normal or cancerous stem cells applicable to discovery, design, development of new therapies, diagnostics, and research tools for liver diseases.

Both Multiple sclerosis and Cancer are issues that are bring increasingly faced by many individuals around the world. MCET is working to find therapies and has already gained considerable depth in their work which is proof they may very well be on their way to great success!
Please read the following for more in depth information: http://www.multicelltech.com/Discovery-Platform-and-Disease-Targets


Many cases are found when patients are coming in to the OR for other problems. MCET has medications which have tested successfully. The pharmaceutical industry is worth billions and both multiple sclerosis and cancer fighting treatments are needed more and more, which makes Multicell Technologies, Inc. even more valued then ever before.